Synaptiflora · raw details

Synaptiflora is an AI-powered microbiome intelligence startup building a foundational platform to understand and predict how the human microbiome influences drug response, disease biology, and product performance across industries.

The platform combines strain-level microbiome indexing, a proprietary ex vivo high-throughput screening system, and machine-learning models trained on large human microbiome datasets. Together, these technologies connect raw microbiome data to real biological mechanisms—revealing how microbes metabolize compounds, modulate immunity, and alter therapeutic outcomes.

Synaptiflora’s initial focus is pharmaceutical R&D, helping partners improve clinical trial success, patient stratification, and drug efficacy by accounting for microbiome-driven variability. The same intelligence layer extends to nutrition, cosmetics, and agriculture, enabling microbiome-aware product design and innovation.

At its core, Synaptiflora turns the microbiome from an unexplained source of noise into a predictive, actionable system for building better, more precise products.